Endocrine Abstracts

Sox9 is a transcription factor of the HMG box DNA binding family involved in chondrocyte differentiation, sexual determination and the development of endoderm-derived-organs. Preliminary results from our laboratory have shown that Sox9 is expressed in the thyroid gland and its regulation is under the control of TSH and TGFβ. In this work we studied the role of Sox9 in the thyroid cells differentiation and its relationship with the other thyroid transcription factors, main...

The transcription factor Sox9 is a member of the HMG-box-DNA binding family essential for chondrocyte differentiation, sexual determination, and the maintenance of the stem/progenitor cells in several tissues. Furthermore, Sox9 is involved in the development of endoderm-derived-organs. Owing to the endodermic origin of the thyroid, we proposed to study the expression of Sox9 in thyroid follicular cells and its regulation by TSH and TGFβ, two main factors involved in thyro...

Undifferentiated thyroid carcinomas are extremely aggressive and currently lack effective treatment. Aberrant RAS-ERK signaling, triggered mainly by BRAF and RAS mutations, is responsible for the occurrence and progression of most thyroid carcinomas, which led to the clinical use of small kinase inhibitors targeting kinases of the pathway. The results were disappointing, because of the emergence of resistance and high-associated toxicity. A more specific approach, targeting si...

It is well-known that the increase of intraprostatic levels of 5α-dihydrotestosterone is related to the development of prostatic pathologies such as benign prostatic hyperplasia and prostate cancer. So finasteride and dutasteride-based therapies have been used to improve these diseases. These drugs are potent inhibitors of the enzyme 5α-reductase, which is found in the androgen-dependent tissues. This enzyme is responsible for converting testosterone into dihydrotest...

Introduction: The availability of an increasing therapeutic arsenal for endocrine diseases seems to explain the current trend towards a decrease in the indications of endocrine surgery. However, this trend requires a detailed study before being confirmed in our setting.Objectives: We aimed to assess the trends in the performance of endocrine surgery, in children and adults, during three consecutive years (2014, 2015 and 2016) in our University Tertiary-C...

Introduction and aim: The current population is experiencing an increase in life expectancy, with a consequent change in the demographic structure of the society. It is common, therefore, to find elderly patients with pituitary neuroendocrine tumors (PitNET) in our usual clinical practice. Currently, there are no specific recommendations for treatment and data of outcomes in elderly are scarce. The aim of our study was to compare the clinical characteristics and surgical outco...

Background: TGR represents the percentage change in tumour volume per month (%/m). Previous results from the GREPONET study (A. Lamarca et al, ENETS 2018) showed that TGR measured after 3 months (TGR3m) of starting systemic treatment (ST) or watch and wait (WW) was an early biomarker predicting progression-free survival (PFS) in NETs.Methods: Pts from 7 centres with advanced grade (G) 1/2 NETs from the pancreas (P)/small bowel (SB) initiating ST...

Introduction: The role of mitotane as an adjuvant therapy for adrenocortical carcinoma (ACC) remains a contentious topic due to the scarcity of robust randomized clinical trials, attributed to the low incidence of this neoplasm. Despite this, the prognosis following surgery for localized tumors is generally poor, leading to varied clinical practices.Methods: This study utilized patient data from the ICARO registry of the GETHY group and SEEN, with diseas...